Angiotensin converting enzyme inhibition unmasks the sympathofacilitatory effect of bradykinin in human right atrium

Journal of Hypertension

Volumn 15, Issue 11, 1997, Pages 1263-1270

  Rump, L Christian ^a   Berlit, Tim ^a   Schwertfeger, Eckhard ^a   Beyersdorf, Friedhelm ^b   Schollmeyer, Peter ^a   Bohmann, Christine ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Herzchirurgie   (Germany)

Author keywords

Angiotensin converting enzyme inhibition; Bradykinin; Noradrenaline release; Prostaglandins; Sympathetic nerves

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BRADYKININ; BRADYKININ B1 RECEPTOR AGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; INDOMETACIN; NORADRENALIN; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROSTIMULATION; ENZYME INHIBITION; HEART RIGHT ATRIUM; HUMAN; HUMAN TISSUE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SYMPATHETIC TONE;

EID: 0030665368     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715110-00010     Document Type: Article

References (44)

1. Regoli D, Barabe J: Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980, 32:1-46.
2. Erdös EG: Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990, 15:S20-S24.
3. Skidgel RA. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol 1992, 20 (suppl 9):S4-S9.
4. 2 receptor. Genomics 1994, 23:362-369
5. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Shneck KA, et al.: Expression cloning of a human B1 bradykinin receptor. J Biol Chem 1994, 269:21583-21586.
6. 2 bradykinin receptor. Proc Natl Acad Sci USA 1991, 88:7724-7728.
7. Hess JF, Borkowski JA, Stonesifer GY, MacNeil T, Strader CD, Ransom RW: Cloning and pharmacological characterization of bradykinin receptors. Brazilian J Med Biol Res 1994, 27:1725-1731.
8. Hall JM: Bradykinin receptors: pharmacological properties and biological roles. Pharmacol Ther 1992, 56:131-190.
9. Linz W, Wiemer G, Gohlke P, Uinger T, Schölkens BA: Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995, 47:25-49.
10. Minshall RD, Yelamanchi VP, Djokovic A, Miletich, Erdös EG, Rabito SF, et al.: Importance of sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat. Circ Res 1994, 74:441-447.
11. Chulak C, Couture R, Foucart S: Modulatory effect of bradykinin on the release of noradrenaline from rat isolated atria. Br J Pharmacol 1995, 115:330-334.
12. Starke K, Peskar BA, Schumacher KA, Taube HD: Bradykinin and postganglionic sympathetic transmission. Naunyn-Schmiedebergs Arch Pharmaco1 1977, 299:23-32.
13. Linz W, Schölkens BA, Han YF: Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol 1986, 8 (suppl 10):S91-S99.
14. Gohlke P, Linger T: Chronic low-dose treatment with perindopril improve cardiac function in stroke-prone spontaneously hypertensive rats by potentiation of endogenous bradykinin. Am J Cardiol 1995, 76:41E-45E,
15. 2-Adrenergic receptor and angiotensin II receptor modulation of sympathetic neurotransmission in human atria. Circ Res 1994, 74:434-440.
16. 2C-Adrenoceptor-modulated release of noradrenaline in human right atrium. Br J Pharmacol 1995, 116:2617-2624.
17. Rump LC, Riera-Knorrenschild G, Schwertfeger E, Bohmann C, Spillner G, Schollmeyer P: Dopaminergic and α-adrenergic control of neurotransmission in human right atrium. J Cardiovasc Pharmacol 1995, 26:462-470.
18. Böke T, Malik KU: Enhancement by locally generated angiotensin II of release of the adrenergic transmitter in the isolated rat kidney. J Pharmacol Exp Ther 1983, 226:900-907.
19. Llona I, Galleguillos X, Belmar J, Huidobro-Toro JP: Bradykinin modulates the release of noradrenaline from vas deferens nerve terminals. Life Sci 1991, 48:2585-2592.
20. 3H]-noradrenaline release in rat hypothalamus. Clin Exp Pharmacol Physiol 1993, 20:787-791.
21. Dominiak P, Simon M, Blöchl A, Brenner P: Changes in peripheral sympathetic outflow of pithed spontaneously hypertensive rats after bradykinin and Des-Arg-bradykinin infusions: influence of converting enzyme inhibition. J Cardiovasc Pharmacol 1992, 20 (suppl 9): S35-S38.
22. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P: Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechansims. Am J Physiol 1993, 264:E631-E637.
23. Rump LC, Bohmann C, Schaible U, Schultze-Seemann W, Schollmeyer PJ: β-Adrenergic, angiotensin II, and bradykinin receptors enhance neurotransmission in human kidney. Hypertension 1995, 26: 445-451.
24. Schwieler JH, Hjemdahl P: Influence of angiotensin-converting enzyme inhibition on sympathetic neurotransmission: possible role of bradykinin and prostaglandins. J Cardiovasc Pharmacol 1992, 20 (suppl 9):S39-S46.
25. Seabrook GR, Bowery BJ, Hill RG: Bradykinin receptors in mouse and rat isolated superior cervical ganglia. Br J Pharmacol 1995, 115:368-372.
26. 2 receptor-mediated chronotropic effect of bradykinin in isolated guinea pig atria. Eur J Pharmacol 1995, 28:17-20.
27. Dendorfer A, Dominiak P: Characterization of bradykinin receptors mediating catecholamine release in PC12 cells. Naunyn-Schmiedebergs Arch Pharmacol 1995, 351:274-281.
28. Vago T: Angiotensin converting enzyme binding sites in human heart and lung: comparison with rat tissues. Br J Pharmacol 1992, 107:821-825
29. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G: Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991, 102:769-773.
30. 2 receptor characterization. Trends Pharmacol Sci 1990, 11:156-161.
31. Félétou M, Martin CAE, Molimard M, Naline E, Germain M, Thurieau C, et al.: In vitro effects of HOE 140 in human bronchial and vascular tissue. Eur J Pnarmacol 1995, 274:57-64.
32. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM: Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995, 77:611-621.
33. Owen PJ, Plevin R, Boarder MR: Characterization of bradykinin-stimulated release of noradrenaline from cultured bovine adrenal chromaffin cells. J Pharmacol Exp Ther 1988, 248:1231-1236.
34. Linz W, Schölkens BA: Role of bradykinin in the cardiac effects of angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol 1992, 20 (suppl 9):S83-S90.
35. 3H]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats. Am J Hypertens 1996, 9:61-69.
36. Trachte GJ: Thromboxane agonist U46619 potentiates noradrenaline efflux from adrenergic nerves. J Pharmacol Exp Ther 1988, 237:473-477.
37. 2-adrenoceptors in rat isolated kidney: involvement of purines and prostaglandins. Naunyn-Schmiedebergs Arch Pharmacol 1993, 347:2273-2279.
38. 3H]-noradrenaline release and vascular tone in rat isolated kidney. Br J Pharmacol 1989, 97:819-828.
39. Greenberg SS, Peevy K, Tanaka TP: Endothelium-derived and intraneuronal nitric oxide-dependent inhibition of noradrenaline efflux from sympathetic nerves by bradykinin. Am J Hypertens 1991, 4:464-467.
40. Malik KU, Nasjletti A: Attenuation by bradykinin of adrenergically-induced vasoconstriction in the isolated perfused kidney of the rabbit: relationship to prostaglandin synthesis. Br J Pharmacol 1979, 67:269-275.
41. Susie H, Nasjletti A, Malik KU: Bradykinin effects on adrenergic transmission in the canine kidney: relation to prostaglandins. Am J Physiol 1981, 241:R146-R151.
42. Ronai AZ: Bradykinin and angiotensin II inhibit neurotransmission in rabbit ear artery by releasing prostanoids. Eur J Pharmacol 1991, 198:93-95.
43. Malik KU: Prostaglandins - modulation of adrenergic nervous system. 1978, 37:203-207.
44. 2 inhibits noradrenaline release and purinergic pressor responses to renal nerve stimulation at 1 Mz in isolated kidneys of young spontaneously hypertensive rats. J Hypertens 1990, 8:897-908.